ClinicalTrials.gg
Active, not recruitingNCT07222917BaxDuo-BalticUpdated Sep 1, 2026

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

A Phase 2 interventional study of Baxdrostat/dapagliflozin and Baxdrostat/Placebo in Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca. Active, not recruiting at 55 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
222
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic — 15 open to participants now, 21 under way, 7 of them phase 3. dapagliflozin · Renal Insufficiency, Chronic.

Enrollment
9th of 40
222 · median 100
Started
2025
with 6 others
Phase 2
12 of 40
4 open now
Primary completion
2026-12
later than 9 of 20 live
Registered
33rd of 40
by date
Lead sponsor
9 of 40
AstraZeneca

Among the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, this one is the 9th largest by enrollment, is one of 7 that started in 2025, is one of 12 in phase 2, reaches primary completion later than 9 of the 20 other live ones, and was the 33rd registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

15 of the 40 studies testing dapagliflozin in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About dapagliflozin

dapagliflozin: first FDA approval 2014 (FARXIGA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 244 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing dapagliflozin in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

International, Multicenter and Double-Blind study. The purpose is to measure the effect of baxdrostat in combination with dapagliflozin compared with baxdrostat/placebo on albuminuria, as well as safety, in participants with chronic kidney disease and high blood pressure.

Read the detailed description

This is a Phase IIb, randomised, multicentre, double-blind, parallel-group study aiming to determine the effect on albuminuria, as well as safety, of baxdrostat/dapagliflozin compared with baxdrostat/placebo, when given to participants with CKD and high blood pressure.

Study population will include participants ≥ 18 years old with CKD. Participants with or without a diagnosis of T2DM and with or without an SGLT2i treatment at screening are eligible for the study.

The study will include an optional pre-screening period, where participants will be assessed for at least one of the following parameters: eGFR, UACR, potassium, sodium, and BP. Participants who are being treated with SGLT2i at the time of the screening visit will complete a washout period After screening and initial confirmation of eligibility, participants will be randomised to receive either baxdrostat/dapagliflozin or baxdrostat/placebo. For randomisation there will be stratification and capping linked to T2DM status.

The primary objective is to assess the effect of baxdrostat/dapagliflozin compared with baxdrostat/matching placebo on albuminuria, which will be evaluated by change from baseline in UACR.

The end of the study is defined as the date of the last visit of the last participant in the study or last scheduled procedure shown in the SoA for the last participant in the study globally, whichever occurs last.

A participant is considered to have completed the study if they have completed all periods of the study including the last scheduled procedure shown in the SoA.

03

Conditions studied

  • Chronic Kidney Disease and Hypertension

Keywords

  • Chronic kidney disease
  • Hypertension
  • Blood pressure
  • Baxdrostat
  • Dapagliflozin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants of any sex and gender must be ≥ 18 years of age at the time of signing the .
  2. Participants with ≥ 30 and \< 90 mL/min/1.73 m2 at screening
  3. Participants with UACR > 200 mg/g (22.6 mg/mmol) and \< 5000 mg/g (565 mg/mmol) at screening
  4. Participants with history of HTN and a SBP ≥ 130 mmHg at screening and ≥ 120 mmHg at the randomisation visit.
  5. Stable and maximum daily tolerated dose of either an ACE inhibitor or an ARB (not both) for at least 4 weeks prior to the screening visit, if not medically .
  6. Participants with:

    1. Serum or plasma potassium ≥ 3.0 and ≤ 4.8 mmol/L if eGFR ≥ 45 mL/min/1.73 m2.
    2. Serum or plasma potassium ≥ 3.0 and ≤ 4.5 mmol/L if eGFR \< 45 mL/min/1.73 m2.
  7. use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Applicable to female participants.

Exclusion criteria

Exclusion Criteria:

  1. Systolic blood pressure > 180 mmHg, or diastolic blood pressure > 110 mmHg at screening.
  2. Known hyperkalaemia, defined as potassium of ≥ 5.5 mmol/L within 3 months before screening
  3. Serum sodium \< 135 mmol/L at the Screening Visit (values obtained within 4 weeks prior to screening or at the Screening Visit).
  4. Diabetes mellitus:

    1. T1DM at the screening visit
    2. Uncontrolled T2DM at screening: > 10.5% (> 91 mmol/mol)
  5. functional HF class IV at screening
  6. Any use of mineralocorticoid receptor antagonists (such as spironolactone, eplerenone, or finerenone), aldosterone synthase inhibitors, potassium-sparing diuretics (such as triamterene or amiloride), or potassium binders (such as sodium zirconium cyclosilicate, patiromer, or sodium polystyrene sulfonate) within 4 weeks prior to screening
  7. Stroke, transient ischaemic cerebral attack, valve implantation or valve replacement, carotid surgery, or carotid angioplasty, acute coronary syndrome, or hospitalisation for worsening HF within previous 3 months prior to randomisation.
  8. Known severe hepatic impairment, defined as Class C, based on records that confirm documented medical history.
  9. Documented history of adrenal insufficiency.
  10. Any dialysis (including for acute kidney injury) within 3 months prior to the screening
  11. Any acute kidney injury within 3 months prior to the screening visit.
  12. Prohibited concomitant medications
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
222 participants (actual)

Study arms

  • Experimental
    Baxdrostat/dapagliflozin

    Participants randomised to the baxdrostat/dapagliflozin arm will receive one dose of baxdrostat and one standard dose of dapagliflozin daily.

    Drug: Baxdrostat/dapagliflozin

  • Placebo comparator
    Baxdrostat /placebo

    Patients will receive one dose of baxdrostat comparator in combination with placebo matching dapagliflozin daily

    Drug: Baxdrostat/Placebo

Interventions

  • DrugBaxdrostat/dapagliflozin

    Drug pages: Baxdrostat · Dapagliflozin

    baxdrostat tablet dapagliflozin tablet

  • DrugBaxdrostat/Placebo

    baxdrostat tablet placebo tablet

06

What researchers measure

Primary outcomes

  1. To determine whether baxdrostat/dapagliflozin is superior to baxdrostat/matching placebo at reducing albuminuria.

    Change from baseline in UACR

    Time frame: Up to 12 weeks

07

Study locations

55 sites
  • Research Site
    Surprise, Arizona 85374, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Port Orange, Florida 32127, United States
  • Research Site
    East Point, Georgia 30344, United States
  • Research Site
    Champaign, Illinois 61822, United States
  • Research Site
    Wichita, Kansas 67214, United States
  • Research Site
    Greenville, North Carolina 27834, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Media, Pennsylvania 19063, United States
  • Research Site
    East Providence, Rhode Island 02914, United States
  • Research Site
    Arlington, Texas 76015, United States
  • Research Site
    Pasadena, Texas 77504, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    Woodbridge, Virginia 22192, United States
  • Research Site
    Ciudad de Buenos Aires, C1425AGC, Argentina
  • Research Site
    Mar del Plata, 7600, Argentina
  • Research Site
    Rosario, S2000CVD, Argentina
  • Research Site
    San Nicolás, B2900DMH, Argentina
  • Research Site
    Sofia, 1756, Bulgaria
  • Research Site
    Yambol, 8600, Bulgaria
  • Research Site
    Courtice, Ontario L1E 2J5, Canada
  • Research Site
    Etobicoke, Ontario M9W 6V1, Canada
  • Research Site
    Stouffville, Ontario L4A1H2, Canada
  • Research Site
    Waterloo, Ontario N2T 0C1, Canada
  • Research Site
    Kaohsiung City, 80756, Taiwan
  • Research Site
    Kaohsiung City, 83301, Taiwan
  • Research Site
    New Taipei City, 235, Taiwan
  • Research Site
    Taichung, 402, Taiwan
  • Research Site
    Taichung, 433004, Taiwan
  • Research Site
    Taipei, 10002, Taiwan
  • Research Site
    Taipei, 110, Taiwan
  • Research Site
    Taoyuan, 333, Taiwan
  • Research Site
    Bangkoknoi, 10700, Thailand
  • Research Site
    Changwat Sara Buri, 18000, Thailand
  • Research Site
    Hat Yai, 90110, Thailand
  • Research Site
    Ratchathewi, 10400, Thailand
  • Research Site
    Adana, 01060, Turkey (Türkiye)
  • Research Site
    Adapazarı, 54290, Turkey (Türkiye)
  • Research Site
    Kahramanmaraş, 46040, Turkey (Türkiye)
  • Research Site
    Kayseri, 38039, Turkey (Türkiye)
  • Research Site
    Kocaeli, 41380, Turkey (Türkiye)
  • Research Site
    Kyiv, 01601, Ukraine
  • Research Site
    Kyiv, 02002, Ukraine
  • Research Site
    Kyiv, 02091, Ukraine
  • Research Site
    Kyiv, 03037, Ukraine
  • Research Site
    Kyiv, 03049, Ukraine
  • Research Site
    Kyiv, 04210, Ukraine
  • Research Site
    Uzhhorod, 88018, Ukraine
  • Research Site
    Vinnytsia, 21029, Ukraine
  • Research Site
    Dundee, DD1 9SY, United Kingdom
  • Research Site
    Liverpool, L9 7AL, United Kingdom
  • Research Site
    London, E1 1FR, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. "Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 80 industry-sponsored phase 2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 31. This study's planned 12 months is below that.

Counting every sponsor, half of 139 studies reached it within 25 months; a quarter within 15 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2025
First posted
Oct 30, 2025
StartActual
Dec 5, 2025
Primary completionEst.
Dec 10, 2026
CompletionEst.
Dec 10, 2026
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07222917
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Oct 30, 2025
Start date
Dec 5, 2025
Primary completion
Dec 10, 2026 (estimated)
Completion
Dec 10, 2026 (estimated)
Last update
Sep 1, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Baxdrostat · Dapagliflozin

Start the discussion